Allstocks.com's Bulletin Board Post New Topic  New Poll  Post A Reply
my profile login | register | search | faq | forum home

  next oldest topic   next newest topic
» Allstocks.com's Bulletin Board » Micro Penny Stocks, Penny Stocks $0.10 & Under » DNAG>>> Gapping on news (Page 1)

 - UBBFriend: Email this page to someone!   This topic comprises 2 pages: 1  2   
Author Topic: DNAG>>> Gapping on news
Prdponce
Member


Member Rated:
4
Icon 1 posted      Profile for Prdponce         Edit/Delete Post   Reply With Quote 
October 25, 2005 - 7:00 AM EDT
DNAG 0.0148 N/A

Today 5d 1m 3m 1y 5y 10y

DNAPrint genomics Licenses Ritalin-Like Compounds Targeting Enhanced Treatment of Drug Addiction and Attention Deficit
DNAPrint genomics, Inc. (OTC BB: DNAG) today announced it has licensed a series of methylphenidate analogs or Ritalin(TM)-like compounds targeting the clinical development of enhanced pharmaceuticals for the treatment of drug addiction, attention deficit hyperactivity disorder (ADHD), and depression. This is the second drug project that will be developed by DNAPrint Pharmaceuticals. Inc., the Company's wholly owned, recently formed pharmaceutical subsidiary focused on personalized medicine.

The licensed compounds are analogs of Ritalin(TM), a well-known drug used for treatment of ADHD. The analogs are designed specifically to have a slow onset and increased half-life in the blood stream, thus reducing a patient's required daily dosage and the potential for drug abuse.

Methylphenidate was first introduced in the 1940s for patients suffering from narcolepsy, a sleeping disorder. Methylphenidate later was found to be useful in treating hyperactive children and adults with depression. One of the drawbacks for methylphenidate is the requirement for multiple daily doses because the drug reaches peak plasma concentrations in two hours and the half-life is only one to three hours, with 80% of the drug excreted during urination. Dosing starts out low and is gradually escalated to a maximum of 60 mg per day for children.

"Our methylphenidate analogs are designed to treat depression and hyperactivity while reducing the required dosing and mitigating significantly the potential for abuse. Additionally, the compounds have potential as treatments for cocaine abuse. In fact, the National Institute for Drug Abuse is advancing one of the compounds in its search for pharmaco-therapies for cocaine abuse," said Dr. Mark Froimowitz, the leading researcher from whom the technology was licensed. "These compounds were designed using molecular modeling and synthesized in a process developed by Dr. Charles Kelley. This research has come out of 25 years of work in the fields of drug addiction, Parkinson's disease and ADHD."

Drs. Froimowitz and Kelley have applied for patents for the newly licensed compounds.

Ritalin(TM) or methylphenidate analogs represent a $4.6 billion dollar market opportunity by 2014, according to the consulting and research firm Decision Resources, Inc. "That's a significant opportunity for DNAPrint genomics and other drug developers," said Richard Gabriel, President and Chief Executive Officer of the Company. "The unique properties of these new compounds coupled with DNAPrint's expertise in determining the inherited gene characteristics of potential patients will enable us to target research on a drug for patients who respond positively to treatment, and hopefully, develop new compounds for those who might reject such a drug."

Dr. Froimowitz and DNAPrint genomics are also working with the National Institute for Drug Abuse (NIDA) in identifying compounds that offer potential relief to the craving usually associated with drug abuse.

"One of the underlying goals is to utilize the newly licensed Froimowitz analogs to develop drugs for patients who do not respond to methylphenidate treatment at all," said Dr. Hector J. Gomez, DNAPrint's Chief Medical Officer. "We are all very excited about combining our ability to identify responder and non-responder patients using genetic ancestry and other clinical markers and target clinical development programs toward those patients."

About DNAPrint genomics, Inc.

DNAPrint genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology and consumer genetic tests. The Company's first theranostic product (drug/test combination) is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Currently in pre-clinical development, PT-401 will be targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint's family of products for the law enforcement forensics and consumer markets include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM).

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

Source: Market Wire (October 25, 2005 - 7:00 AM EDT)

News by QuoteMedia
www.quotemedia.com

Posts: 5120 | Registered: Jun 2004  |  IP: Logged | Report this post to a Moderator
lilpennypincher
Member


Member Rated:
4
Icon 1 posted      Profile for lilpennypincher         Edit/Delete Post   Reply With Quote 
looks good

--------------------
Lil,

Dont LOSE more than you can afford to invest....LOL

I'm buying low and selling into the run...

Posts: 8024 | From: Joisey....see attitude above | Registered: Jan 2004  |  IP: Logged | Report this post to a Moderator
Prdponce
Member


Member Rated:
4
Icon 1 posted      Profile for Prdponce         Edit/Delete Post   Reply With Quote 
getting some hits. lest see how it goes
Posts: 5120 | Registered: Jun 2004  |  IP: Logged | Report this post to a Moderator
Prdponce
Member


Member Rated:
4
Icon 1 posted      Profile for Prdponce         Edit/Delete Post   Reply With Quote 
moving

.0155 x .016

Posts: 5120 | Registered: Jun 2004  |  IP: Logged | Report this post to a Moderator
lilpennypincher
Member


Member Rated:
4
Icon 1 posted      Profile for lilpennypincher         Edit/Delete Post   Reply With Quote 
moving up now

--------------------
Lil,

Dont LOSE more than you can afford to invest....LOL

I'm buying low and selling into the run...

Posts: 8024 | From: Joisey....see attitude above | Registered: Jan 2004  |  IP: Logged | Report this post to a Moderator
Prdponce
Member


Member Rated:
4
Icon 1 posted      Profile for Prdponce         Edit/Delete Post   Reply With Quote 
yeap. it moves well on news
Posts: 5120 | Registered: Jun 2004  |  IP: Logged | Report this post to a Moderator
Prdponce
Member


Member Rated:
4
Icon 1 posted      Profile for Prdponce         Edit/Delete Post   Reply With Quote 
.0163 x .0164
Posts: 5120 | Registered: Jun 2004  |  IP: Logged | Report this post to a Moderator
lilpennypincher
Member


Member Rated:
4
Icon 1 posted      Profile for lilpennypincher         Edit/Delete Post   Reply With Quote 
Have to break that .0164!

--------------------
Lil,

Dont LOSE more than you can afford to invest....LOL

I'm buying low and selling into the run...

Posts: 8024 | From: Joisey....see attitude above | Registered: Jan 2004  |  IP: Logged | Report this post to a Moderator
Prdponce
Member


Member Rated:
4
Icon 1 posted      Profile for Prdponce         Edit/Delete Post   Reply With Quote 
yes that seems to be the resistance
Posts: 5120 | Registered: Jun 2004  |  IP: Logged | Report this post to a Moderator
lilpennypincher
Member


Member Rated:
4
Icon 1 posted      Profile for lilpennypincher         Edit/Delete Post   Reply With Quote 
couldn't break that .0164, here is the dip. If there is momo it may break it on the next run up.

--------------------
Lil,

Dont LOSE more than you can afford to invest....LOL

I'm buying low and selling into the run...

Posts: 8024 | From: Joisey....see attitude above | Registered: Jan 2004  |  IP: Logged | Report this post to a Moderator
Prdponce
Member


Member Rated:
4
Icon 1 posted      Profile for Prdponce         Edit/Delete Post   Reply With Quote 
if it does not do it now is all over. LOL
Posts: 5120 | Registered: Jun 2004  |  IP: Logged | Report this post to a Moderator
lilpennypincher
Member


Member Rated:
4
Icon 1 posted      Profile for lilpennypincher         Edit/Delete Post   Reply With Quote 
ging back up. Have to break .0164 on this one!

--------------------
Lil,

Dont LOSE more than you can afford to invest....LOL

I'm buying low and selling into the run...

Posts: 8024 | From: Joisey....see attitude above | Registered: Jan 2004  |  IP: Logged | Report this post to a Moderator
lilpennypincher
Member


Member Rated:
4
Icon 1 posted      Profile for lilpennypincher         Edit/Delete Post   Reply With Quote 
I'm out. Good luck all!

--------------------
Lil,

Dont LOSE more than you can afford to invest....LOL

I'm buying low and selling into the run...

Posts: 8024 | From: Joisey....see attitude above | Registered: Jan 2004  |  IP: Logged | Report this post to a Moderator
Prdponce
Member


Member Rated:
4
Icon 1 posted      Profile for Prdponce         Edit/Delete Post   Reply With Quote 
got out too.. NEXTTTTTTTT
Posts: 5120 | Registered: Jun 2004  |  IP: Logged | Report this post to a Moderator
Persia
Member


Rate Member
Icon 1 posted      Profile for Persia     Send New Private Message       Edit/Delete Post   Reply With Quote 
DNAPrint genomics Receives Notice of Allowance for Patent for Processing Gene Sequence Data
10/27/05

SARASOTA, Fla., Oct 27, 2005 (PRIMEZONE via COMTEX) --
DNAPrint genomics, Inc. (OTCBB:DNAG), a developer of genomics-based products and services, today announced that it has been granted a notice of allowance from the U.S. Patent and Trademark Office for its patent application for Efficient Methods and Apparatus for High-Throughput Processing of Gene Sequence Data.

"Though we are all 99.9% identical at the level of our DNA, it is the 0.1% difference called polymorphism that accounts for our individuality," stated Tony N. Frudakis, Ph.D., DNAPrint's founder and Chief Scientific Officer. "The technology our patent application covers relates to methods useful for measuring polymorphisms in and around genes that are part of large gene families, a task that traditionally has been problematic for the molecular genetics community."

Geneticists use "molecular addresses" to query and study specific genes much like a postman uses a street address to find the recipient of a letter. The methods covered in the patent are useful when there are several genes with the same or substantially similar "sequence" addresses. Many of the genes that are involved in drug metabolism and response are members of large gene families.

This is the first patent for which the Company applied. The methods covered in the application, first drafted in 2001, were originally developed to power DNAPrint's unique approach to pharmacogenomics research, which is aimed at understanding why people respond uniquely to drugs.

About DNAPrint genomics, Inc.

DNAPrint genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology and consumer genetic tests. The Company's first theranostic product (drug/test combination) is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Currently in pre-clinical development, PT-401 will be targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint's family of products for the law enforcement forensics and consumer markets include DNAWITNESS, RETINOME, ANCESTRYbyDNA and EURO-DNA.

Posts: 1364 | From: Somebody from Europe | Registered: Sep 2005  |  IP: Logged | Report this post to a Moderator
Persia
Member


Rate Member
Icon 1 posted      Profile for Persia     Send New Private Message       Edit/Delete Post   Reply With Quote 
Maybe today is the day...
Posts: 1364 | From: Somebody from Europe | Registered: Sep 2005  |  IP: Logged | Report this post to a Moderator
bmarley5780
Member


Member Rated:
4
Icon 1 posted      Profile for bmarley5780         Edit/Delete Post   Reply With Quote 
http://stockcharts.com/def/servlet/SC.web?c=DNAG,uu[h,a]daclyyay[pb50!b200][vc60][iUb14!La12,26,9]&pref=G

oversold...
MACD looks to be goin to the right direction...

Posts: 1533 | From: jacksonville, nc, usa | Registered: Dec 2004  |  IP: Logged | Report this post to a Moderator
SFC_Jordan
Member


Member Rated:
4
Icon 1 posted      Profile for SFC_Jordan     Send New Private Message       Edit/Delete Post   Reply With Quote 
SARASOTA, FL, Nov 01, 2005 (MARKET WIRE via COMTEX) -- DNAPrint(TM) genomics,
Inc. (OTC BB: DNAG), a developer of genomics-based products and services, today
announced that it has acquired Kenna Technologies, Inc., of West Chester, Pa., a
private company which builds computer models that mimic complex biological
systems.

Under terms of the agreement, Kenna's shareholders exchanged all of the
company's outstanding shares for 1.5 million shares of DNAPrint genomics Common
Stock. The transaction was effective on Tuesday, Oct. 25, 2005.

"The acquisition of Kenna and its computational biology process, provides
substantial synergies with our pharmacogenomics applications," stated Hector J.
Gomez, M.D., Ph.D., Chairman and Chief Medical Officer of DNAPrint genomics. "We
believe Kenna's technologies will lead to shorter and less expensive drug
development times, and represent a powerful tool in our company's search to
develop programs for personalized medicine, and test/drug combinations targeting
a specific group of patients."

Computational biology models (also called In silico technology,) incorporate the
vast datasets and fragmented knowledge of experimentalists and can be a crucial
requirement when developing effective therapies and diagnostic products.

"Initially, the Kenna team will support the clinical development of DNAPrint's
PT-401 Super EPO erythropoietin dimer for the treatment of anemia and renal
failure," stated Kenna co-founder Barbara Handelin, Ph.D, who joins DNAPrint as
Director of Diagnostics and General Manager of Computational Biology. "We will
provide simulations to help design optimal clinical trials with respect to
dosing, patient selection factors and trial duration."

As a result of the acquisition, DNAPrint also gains access to Kenna's
BoneFusion(TM) and CellCycleFusion(TM) models. BoneFusion simulates the
processes in bone remodeling that underlie diseases like osteoporosis, while
CellCycleFusion simulates the molecular pathways that control basic cellular
functions. These pathways are common targets of current cancer therapies.

"Simply put, DNAPrint will utilize computational modeling to develop drugs more
efficiently," said DNAPrint President and Chief Executive Officer Richard
Gabriel. "It will play a valuable role in our Company's efforts to pursue the
development of drugs which maximize efficacy and minimize side effects by
tailoring medications for specific individuals and well-defined population
sectors."

About DNAPrint

DNAPrint genomics, Inc. (www.dnaprint.com) is a developer of genomics-based
products and services focused on drug development, pharmacogenomic diagnostic
tests, forensics technology and consumer genetic tests. The Company's first
theranostic product (drug/test combination) is PT-401, a "Super EPO"
(erythropoietin) dimer protein drug for treatment of anemia in renal dialysis
patients (end stage renal disease). Currently in pre-clinical development,
PT-401 will be targeted to patients with a genetic profile indicating their
propensity to have the best clinical response. DNAPrint's family of products for
the law enforcement forensics and consumer markets include DNAWITNESS(TM),
RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM).

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking
statements. Such statements are subject to risks and uncertainties that could
cause actual results to differ materially from those projected, including, but
not limited to, uncertainties relating to technologies, product development,
manufacturing, market acceptance, cost and pricing of DNAPrint's products,
dependence on collaborations and partners, regulatory approvals, competition,
intellectual property of others, and patent protection and litigation. DNAPrint
genomics, Inc. expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements contained
herein to reflect any change in DNAPrint's expectations with regard thereto or
any change in events, conditions, or circumstances on which any such statements
are based.


Company Contact:

Richard Gabriel

President and CEO

941-366-3400

-or-

Ron Stabiner

The Wall Street Group, Inc.

212-888-4848

SOURCE: DNAprint Genomics, Inc.

--------------------
Army guy just trying to make a few bucks....

Posts: 293 | From: Rhode Island | Registered: Oct 2005  |  IP: Logged | Report this post to a Moderator
Persia
Member


Rate Member
Icon 1 posted      Profile for Persia     Send New Private Message       Edit/Delete Post   Reply With Quote 
DNAPrint Genomics Executives to Attend World Drug Discovery & Development Conference in Copenhagen
11/4/05

SARASOTA, FL, Nov 04, 2005 (MARKET WIRE via COMTEX) --
DNAPrint(TM) genomics, Inc. (OTC BB: DNAG), a developer of genomics-based products and services, today announced that it will be participating in the World Drug Discovery & Development Summit on Tuesday and Wednesday, Nov. 29-30, 2005 in Copenhagen, Denmark.

"The Summit comes at a time when DNAPrint genomics is actively pursuing the development of pharmacogenomic products that include test/drug combinations based on inherited gene characteristics. These test/drug combinations are designed to optimize patient response and improve efficacy," stated Hector J. Gomez, M.D., Ph.D., the Company's Chairman and Chief Medical Officer. "The Summit is an excellent opportunity to participate in targeted meetings with pharmaceutical industry representatives and to discuss our Company's advances in the field of personalized medicine."

Other top DNAPrint executives attending the summit, which is sponsored by the London-based World Trade Group, are President and Chief Executive Office Richard Gabriel and Company Founder and Chief Scientific Officer Tony N. Frudakis.

"This conference presents us a forum to showcase not only our drug development, but also how our technologies, products and services can help the pharmaceutical companies accelerate their own research and development programs," Mr. Gabriel said.

"The development of pharmaceuticals that improve the quality of life for medical patients has been an over-riding goal of our Company from its beginning," Dr. Frudakis stated. "Our research in drug development is well under-way and our newly formed DNAPrint Pharmaceutical subsidiary emphasizes the importance we place on this objective."

Posts: 1364 | From: Somebody from Europe | Registered: Sep 2005  |  IP: Logged | Report this post to a Moderator
Persia
Member


Rate Member
Icon 1 posted      Profile for Persia     Send New Private Message       Edit/Delete Post   Reply With Quote 
190 x 192
Posts: 1364 | From: Somebody from Europe | Registered: Sep 2005  |  IP: Logged | Report this post to a Moderator
Persia
Member


Rate Member
Icon 1 posted      Profile for Persia     Send New Private Message       Edit/Delete Post   Reply With Quote 
194 x 195
Posts: 1364 | From: Somebody from Europe | Registered: Sep 2005  |  IP: Logged | Report this post to a Moderator
Persia
Member


Rate Member
Icon 1 posted      Profile for Persia     Send New Private Message       Edit/Delete Post   Reply With Quote 
197 x 198
Posts: 1364 | From: Somebody from Europe | Registered: Sep 2005  |  IP: Logged | Report this post to a Moderator
Persia
Member


Rate Member
Icon 1 posted      Profile for Persia     Send New Private Message       Edit/Delete Post   Reply With Quote 
204 x 205

It's going up boys and girls.

Posts: 1364 | From: Somebody from Europe | Registered: Sep 2005  |  IP: Logged | Report this post to a Moderator
Persia
Member


Rate Member
Icon 1 posted      Profile for Persia     Send New Private Message       Edit/Delete Post   Reply With Quote 
209 x 210

Flying! [Smile]

Posts: 1364 | From: Somebody from Europe | Registered: Sep 2005  |  IP: Logged | Report this post to a Moderator
Persia
Member


Rate Member
Icon 1 posted      Profile for Persia     Send New Private Message       Edit/Delete Post   Reply With Quote 
213 x 217
Posts: 1364 | From: Somebody from Europe | Registered: Sep 2005  |  IP: Logged | Report this post to a Moderator
Persia
Member


Rate Member
Icon 1 posted      Profile for Persia     Send New Private Message       Edit/Delete Post   Reply With Quote 
A first dip here.
Posts: 1364 | From: Somebody from Europe | Registered: Sep 2005  |  IP: Logged | Report this post to a Moderator
SFC_Jordan
Member


Member Rated:
4
Icon 1 posted      Profile for SFC_Jordan     Send New Private Message       Edit/Delete Post   Reply With Quote 
Big boys are selling, im out at .0215

--------------------
Army guy just trying to make a few bucks....

Posts: 293 | From: Rhode Island | Registered: Oct 2005  |  IP: Logged | Report this post to a Moderator
Persia
Member


Rate Member
Icon 1 posted      Profile for Persia     Send New Private Message       Edit/Delete Post   Reply With Quote 
Out at 213.

Nice run to start the day with.

Posts: 1364 | From: Somebody from Europe | Registered: Sep 2005  |  IP: Logged | Report this post to a Moderator
BigBuyer100
Member


Icon 1 posted      Profile for BigBuyer100         Edit/Delete Post   Reply With Quote 
Motge is going to run soon.
Posts: 541 | From: Virginia | Registered: Nov 2005  |  IP: Logged | Report this post to a Moderator
matto
Member


Member Rated:
4
Icon 1 posted      Profile for matto         Edit/Delete Post   Reply With Quote 
still in and running this till it hits 40%

--------------------
Trading is a blast!!

Posts: 4921 | From: Rhode Island | Registered: May 2005  |  IP: Logged | Report this post to a Moderator
SFC_Jordan
Member


Member Rated:
4
Icon 1 posted      Profile for SFC_Jordan     Send New Private Message       Edit/Delete Post   Reply With Quote 
Matto, great job. you brave sole you. LOL

--------------------
Army guy just trying to make a few bucks....

Posts: 293 | From: Rhode Island | Registered: Oct 2005  |  IP: Logged | Report this post to a Moderator
tara81662l
Member


Member Rated:
5
Icon 1 posted      Profile for tara81662l     Send New Private Message       Edit/Delete Post   Reply With Quote 
Just saw this. More people hearing about DNAG!

OTC ADVISORS, LLC: www.otc-advisors.com "BULLS IN THE STABLE" CEOA, DNAG, IVCM, MOBL


By M2
Last Update: 11/4/2005 10:33:23 AM Data provided by

NY, Nov 04, 2005 (M2 PRESSWIRE via COMTEX) -- www.otc-advisors.com "Bull's in the stable" CEO America, Inc. (CEOA), DNAPrint(TM)genomics, Inc. (DNAG),IVI Communications Inc. (IVCM) and MobilePro Corp. (MOBL)

Posts: 11 | Registered: Oct 2005  |  IP: Logged | Report this post to a Moderator
Malloy
Member


Member Rated:
4
Icon 1 posted      Profile for Malloy     Send New Private Message       Edit/Delete Post   Reply With Quote 
No. 1 traded OTC penny today...this one,s hot.
Posts: 2691 | Registered: Dec 2003  |  IP: Logged | Report this post to a Moderator
Malloy
Member


Member Rated:
4
Icon 1 posted      Profile for Malloy     Send New Private Message       Edit/Delete Post   Reply With Quote 
Going to test hod again...still on the top listed trading stocks today.

--------------------
Malloy
-----------------------

Posts: 2691 | Registered: Dec 2003  |  IP: Logged | Report this post to a Moderator
kilerb
Member


Icon 1 posted      Profile for kilerb     Send New Private Message       Edit/Delete Post   Reply With Quote 
Where do you guys seeing this one going? Is it just having it's day in the sun because of news and then it's bye bye again?
Posts: 1031 | Registered: Sep 2005  |  IP: Logged | Report this post to a Moderator
  This topic comprises 2 pages: 1  2   

Quick Reply
Message:

HTML is not enabled.
UBB Code™ is enabled.

Instant Graemlins
   


Post New Topic  New Poll  Post A Reply Close Topic   Feature Topic   Move Topic   Delete Topic next oldest topic   next newest topic
 - Printer-friendly view of this topic
Hop To:


Contact Us | Allstocks.com Message Board Home

© 1997 - 2021 Allstocks.com. All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2

Share